Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fangzhou Inc.

方舟云康控股有限公司

(A company incorporated in the Cayman Islands with limited liability)

(Stock code: 6086)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2025

Reference is made to the annual report of Fangzhou Inc. (the "**Company**", together with its subsidiaries and the Consolidated Affiliated Entities, the "**Group**") for the year ended December 31, 2025 ("**FY2025**") published on April 24, 2026 (the "**2025 Annual Report**") and the prospectus of the Company dated June 28, 2024 (the "**Prospectus**"). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the 2025 Annual Report and the Prospectus.

In addition to the information disclosed in the 2025 Annual Report, the Company would like to provide the following supplemental information.

1. USE OF PROCEEDS FROM THE GLOBAL OFFERING

As disclosed in the 2025 Annual Report, the net proceeds from the Global Offering were approximately HK$67.09 million. Pursuant to paragraphs 11(8) and 11A of Appendix D2 to the Listing Rules, the Company wishes to supplement the 2025 Annual Report with the amount of unutilized net proceeds as of January 1, 2025. This amount, corresponding to the unutilized net proceeds as of December 31, 2024 as previously disclosed in the annual report of the Company for the year ended December 31, 2024, is set out in the table below under the column headed "Unutilized net proceeds as of January 1, 2025", and should be read in conjunction with the section headed "Directors' Report — Use of Proceeds from the Global Offering" in the 2025 Annual Report. Save for the inclusion of the column headed "Unutilized net proceeds as of January 1, 2025", all other figures and information in the table remain unchanged from those disclosed in the 2025 Annual Report:

Use of proceeds from the Global Offering	Amount of net proceeds for planned applications *(HK$ million)*	Percentage of total net proceeds *(%)*	Unutilized net proceeds as of January 1, 2025 *(HK$ million)*	Utilized net proceeds during FY2025 *(HK$ million)*	Utilized net proceeds as of December 31, 2025 *(HK$ million)*	Unutilized net proceeds as of December 31, 2025 *(HK$ million)*	Expected time frame for unutilized amount
Business expansion	**45.22**	**67.4%**	**31.38**	**22.19**	**36.03**	**9.19**	**Before December 2028**
1. Promoting brand awareness	11.61	17.3%	6.08	6.08	11.61	–	–
2. Enhancing user growth and engagement, and maintaining a highly active user base	14.42	21.5%	10.26	7.87	12.03	2.39	Before December 2028
3. Attracting and retaining talent, especially those with extensive experience in media and technology-powered medical services and insights in the field of chronic disease management	15.50	23.1%	11.35	6.22	10.37	5.13	Before December 2028
4. Expanding product offerings and enhancing supply chain capabilities	3.69	5.5%	3.69	2.02	2.02	1.67	Before December 2028
Research and development activities	**10.74**	**16.0%**	**7.41**	**4.98**	**8.31**	**2.43**	**Before December 2028**
1. Recruiting a team of approximately 40 software engineers by 2028, of which 70% are senior software engineers and the remainder are junior software engineers	4.70	7.0%	3.24	2.18	3.64	1.06	Before December 2028

Use of proceeds from the Global Offering	Amount of net proceeds for planned applications *(HK$ million)*	Percentage of total net proceeds *(%)*	Unutilized net proceeds as of January 1, 2025 *(HK$ million)*	Utilized net proceeds during FY2025 *(HK$ million)*	Utilized net proceeds as of December 31, 2025 *(HK$ million)*	Unutilized net proceeds as of December 31, 2025 *(HK$ million)*	Expected time frame for unutilized amount
2. (i) improve the application of AI technology and big data analysis capabilities in CDM to more accurately capture user habits throughout their activities, from seeking consultations, purchasing pharmaceutical products to their preferences for viewing content on our platform, thereby improving user experience and improving the conversion rate of paying users on our platform; (ii) optimize our infrastructure in various technological areas, such as (a) computer vision, to improve the efficiency of order identification and processing and user information management, (b) natural language processing, to optimize the question-answering engine of our AI medical assistant, and (c) search-based recommendation algorithms to deliver the most relevant information catered to users' evolving needs; (iii) improve stability of the system to withstand the increasing pressure as we scale our online operations; and (iv) optimize the functions of our WeChat mini programs and perform routine system upgrade and maintenance	6.04	9.0%	4.17	2.80	4.67	1.37	Before December 2028
Potential investments and acquisitions or strategic alliances with other stakeholders in the value chain of the online CDM industry	**7.78**	**11.6%**	**7.78**	**4.55**	**4.55**	**3.23**	**Before December 2028**
Working capital and general corporate purposes	**3.35**	**5.0%**	**2.68**	**1.96**	**2.63**	**0.72**	**Before December 2028**
Total	**67.09**	**100.0%**	**49.25**	**33.68**	**51.52**	**15.57**	

2. ANNUAL REVIEW BY THE INDEPENDENT NON-EXECUTIVE DIRECTORS IN CONNECTION WITH THE CONTRACTUAL ARRANGEMENTS

As stated in the Prospectus, the Company has adopted certain measures to ensure good corporate governance standards and to avoid potential conflicts of interest between the Group and the Controlling Shareholders. Accordingly, the independent non-executive Directors have conducted an annual review on the Contractual Arrangements in respect of FY2025 on whether there are any conflicts of interests between the Group and the Controlling Shareholders, and the Controlling Shareholders have provided all information necessary to the independent non-executive Directors for the purpose of their annual review. The independent non-executive Directors confirmed that they are not aware of any conflicts of interests between the Group and the Controlling Shareholders during FY2025.

The above supplemental information does not affect other information contained in the 2025 Annual Report. Save as disclosed above, all other information contained in the 2025 Annual Report remains unchanged.

By order of the Board
Fangzhou Inc.
Mr. WANG Haijiao
Chief Executive Officer and Executive Director

Hong Kong, November 6, 2026

As of the date of this announcement, the Board comprises Mr. WANG Haijiao, Mr. ZHOU Feng and Mr. ZOU Yuming as executive Directors, Mr. David McKee HAND as non-executive Director, and Ms. KANG Wei, Dr. WANG Haizhong and Mr. ZHU Xiaolu as independent non-executive Directors.